Salvatore Grimaldi, DO
Facial Plastic Surgery · West Palm Beach, FLNPI 1083735401
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Philadelphia Medical Management Company LLC accounts for 98.4% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $166,534, more than ten times the $1,058 reported in 2019. Among facial plastic surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $2199.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philadelphia Medical Management Company LLC$305K
- Medtronic$1K
- Regeneron Healthcare Solutions, Inc.$763
- Optinose US, Inc.$720
- Intersect ENT, Inc.$601
- GSK$246
- plus $1K from 16 others
Across 3 payments — averaging $4156.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerin Medical Inc.$12K
What the payments were for
- Consulting fees$165,70953%
- Speaking & faculty fees$139,58545%
- Food & beverage$4,7522%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philadelphia Medical Management Company LLC | 2 | $305,294 |
| Medtronic(2 entities) | 20 | $1,014 |
| Regeneron Healthcare Solutions, Inc. | 28 | $763 |
| Optinose US, Inc. | 17 | $720 |
| Intersect ENT, Inc. | 8 | $601 |
| GSK | 12 | $246 |
| Sanofi | 8 | $239 |
| Acclarent, Inc | 4 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $190 |
| Stryker | 3 | $162 |
| Neurent Medical Limited | 1 | $141 |
| Aerin Medical Inc. | 10 | $124 |
| Alk-abello, Inc | 4 | $75 |
| Kaleo, Inc. | 4 | $69 |
| Shire North American Group Inc | 3 | $61 |
| Merck | 2 | $37 |
| Smith+Nephew | 2 | $33 |
| Phadia US Inc. | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Coopersurgical, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROPEL$885
- Xhance$463
- NEUROMARK Device$141
- NEUROMARK Radiofrequency Console$141
- SINUVA$138
- NUVENT$135
- XPRESS ENT DILATION SYSTEM$124
- TruDi$105
How this compares
$310,103 in reported general payments places this provider in the 95th percentile of 49 facial plastic surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Epinephrine | 102 | $16,158 |
| Fluticasone Propionate | 846 | $11,585 |
| Ipratropium Bromide | 407 | $10,993 |
| Azelastine Hcl | 181 | $4,928 |
| Famotidine | 573 | $4,319 |
| Montelukast Sodium | 575 | $3,697 |
| Omeprazole | 296 | $2,486 |
| Cefdinir | 137 | $2,370 |
| Fluocinolone Acetonide Oil | 25 | $1,059 |
| Doxycycline Monohydrate | 81 | $845 |
| Methylprednisolone | 155 | $833 |
| Clotrimazole | 35 | $783 |
| Mupirocin | 126 | $779 |
| Ofloxacin | 33 | $633 |
| Mometasone Furoate | 34 | $625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $19 | $16,158102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 facial plastic surgery providers in Florida.
Other facial plastic surgery in West Palm Beach
- Patrick ClevelandWest Palm Beach$2K
- Ryan GreeneWeston$101K
- Curtis JohnsonPlantation$37K
- John HolcombSarasota$23K
- Vijay SharmaJupiter$16K
- Zeeshan AzizFernandina Beach$15K
- Wilson DumornayPlantation$9K
- Deidre LeakeSt Augustine$8K
- Nathan NachlasBoca Raton$5K
- Nikolaus HjelmMiami$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.